JP6016234B2 - ビタミンb部分構造を持つ粘膜付着性ポリマー - Google Patents
ビタミンb部分構造を持つ粘膜付着性ポリマー Download PDFInfo
- Publication number
- JP6016234B2 JP6016234B2 JP2012531410A JP2012531410A JP6016234B2 JP 6016234 B2 JP6016234 B2 JP 6016234B2 JP 2012531410 A JP2012531410 A JP 2012531410A JP 2012531410 A JP2012531410 A JP 2012531410A JP 6016234 B2 JP6016234 B2 JP 6016234B2
- Authority
- JP
- Japan
- Prior art keywords
- disulfide
- nicotinamide
- iso
- mercapto
- mercaptopyridoxine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920002807 Thiomer Polymers 0.000 title claims description 23
- 229930003270 Vitamin B Natural products 0.000 title 1
- 235000019156 vitamin B Nutrition 0.000 title 1
- 239000011720 vitamin B Substances 0.000 title 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 73
- 229920000642 polymer Polymers 0.000 claims description 70
- 150000001875 compounds Chemical class 0.000 claims description 52
- 229960003966 nicotinamide Drugs 0.000 claims description 36
- 235000005152 nicotinamide Nutrition 0.000 claims description 36
- 239000011570 nicotinamide Substances 0.000 claims description 36
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 35
- -1 nicotinamide-disulfide chain Chemical group 0.000 claims description 29
- WLOURXVESYABHO-UHFFFAOYSA-N 5-hydroxy-3,4-bis(hydroxymethyl)-6-methyl-1H-pyridine-2-thione Chemical compound CC1=NC(S)=C(CO)C(CO)=C1O WLOURXVESYABHO-UHFFFAOYSA-N 0.000 claims description 15
- LCHHBVLZCPIONY-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-(sulfanylmethyl)pyridin-3-ol Chemical compound OCC1=CN=C(CS)C(O)=C1CO LCHHBVLZCPIONY-UHFFFAOYSA-N 0.000 claims description 11
- 229920001661 Chitosan Polymers 0.000 claims description 11
- 230000003232 mucoadhesive effect Effects 0.000 claims description 11
- 239000001814 pectin Substances 0.000 claims description 10
- 229920001277 pectin Polymers 0.000 claims description 10
- 229920002554 vinyl polymer Polymers 0.000 claims description 10
- 238000006116 polymerization reaction Methods 0.000 claims description 9
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000000783 alginic acid Substances 0.000 claims description 6
- 229960001126 alginic acid Drugs 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 235000010987 pectin Nutrition 0.000 claims description 6
- 229920000193 polymethacrylate Polymers 0.000 claims description 6
- 229920000656 polylysine Polymers 0.000 claims description 5
- 229920002714 polyornithine Polymers 0.000 claims description 5
- 108010055896 polyornithine Proteins 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 3
- 125000002228 disulfide group Chemical group 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 150000001409 amidines Chemical class 0.000 claims 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- JWGLQVHQUBWDSP-UHFFFAOYSA-N 2-sulfanylidene-1h-pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CNC1=S JWGLQVHQUBWDSP-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- PWSJCBQLHHENIG-UHFFFAOYSA-N 6-sulfanylidene-1h-pyridine-3-carboxamide Chemical compound NC(=O)C=1C=CC(=S)NC=1 PWSJCBQLHHENIG-UHFFFAOYSA-N 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 150000003573 thiols Chemical class 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000006177 thiolation reaction Methods 0.000 description 3
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 3
- 150000003698 vitamin B derivatives Chemical class 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- WYKHFQKONWMWQM-UHFFFAOYSA-N 2-sulfanylidene-1h-pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1S WYKHFQKONWMWQM-UHFFFAOYSA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- WCDSVWRUXWCYFN-UHFFFAOYSA-N 4-aminobenzenethiol Chemical compound NC1=CC=C(S)C=C1 WCDSVWRUXWCYFN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- KIUYINLYNRFJLM-UHFFFAOYSA-N chlorothiourea Chemical compound NC(=S)NCl KIUYINLYNRFJLM-UHFFFAOYSA-N 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960003151 mercaptamine Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000083 poly(allylamine) Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 description 1
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 1
- ZQZAHPFFZWEUCL-UHFFFAOYSA-N 2-chloropyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1Cl ZQZAHPFFZWEUCL-UHFFFAOYSA-N 0.000 description 1
- OFKBYKHFMXAXSG-UHFFFAOYSA-N 2-sulfanylidene-1h-pyridine-4-carboxamide Chemical compound NC(=O)C1=CC=NC(S)=C1 OFKBYKHFMXAXSG-UHFFFAOYSA-N 0.000 description 1
- VTWPDRWUHYJHAS-UHFFFAOYSA-N 2-sulfanylpropanimidamide Chemical compound CC(S)C(N)=N VTWPDRWUHYJHAS-UHFFFAOYSA-N 0.000 description 1
- KSLINXQJWRKPET-UHFFFAOYSA-N 3-ethenyloxepan-2-one Chemical compound C=CC1CCCCOC1=O KSLINXQJWRKPET-UHFFFAOYSA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- DTRIDVOOPAQEEL-UHFFFAOYSA-M 4-sulfanylbutanoate Chemical compound [O-]C(=O)CCCS DTRIDVOOPAQEEL-UHFFFAOYSA-M 0.000 description 1
- CTDLTFLXHNPTCY-UHFFFAOYSA-N 6-chloro-4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CC1=NC(Cl)=C(CO)C(CO)=C1O CTDLTFLXHNPTCY-UHFFFAOYSA-N 0.000 description 1
- ZIJAZUBWHAZHPL-UHFFFAOYSA-N 6-chloropyridine-3-carboxamide Chemical compound NC(=O)C1=CC=C(Cl)N=C1 ZIJAZUBWHAZHPL-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 0 C[C@H](CC1)C[C@@H](C)C1[Cn] Chemical compound C[C@H](CC1)C[C@@H](C)C1[Cn] 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- CYAORCLYOCUOTI-UHFFFAOYSA-N N1=C(C)C(O)=C(CO)C(CO)=C1.SC1=NC=C(C=C1)C1N(C)CCC1 Chemical compound N1=C(C)C(O)=C(CO)C(CO)=C1.SC1=NC=C(C=C1)C1N(C)CCC1 CYAORCLYOCUOTI-UHFFFAOYSA-N 0.000 description 1
- MQTVJUZUVLBEBG-WCCKRBBISA-N NC(=O)C=C.CC(=O)SC[C@H](N)C(O)=O Chemical compound NC(=O)C=C.CC(=O)SC[C@H](N)C(O)=O MQTVJUZUVLBEBG-WCCKRBBISA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical class Cl* 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 108010054561 gastric mucus glycoproteins Proteins 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- GDJYIXGPYCKDOV-UHFFFAOYSA-N n-phenylthiohydroxylamine Chemical compound SNC1=CC=CC=C1 GDJYIXGPYCKDOV-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical group OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/54—Polymers characterized by specific structures/properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
Description
ポリアクリル酸システアミン共役(polyacrylic acid-cysteamine conjugates)の様な、チオール化された(架橋)ポリ(メタ)アクリレート(thiolated (crosslinked)poly(meth)acrylates) [Hombach et al., J Pharm Sci. 98、(2009) 555-564]、又はポリカルボフィル−システイン共役(polycarbophil-cysteine conjugates) [Vetter et al.,J Pharm Sci. 99 (2010) 1427-1439]、キトサン−チオグリコール酸共役(chitosan-thioglycolic acid conjugates)の様なチオール化されたキトサン(thiolated chitosans) [Bernkop-Schnurch及びHopf Sci. Pharm., 69 (2001) 109-118], キトサン メルカプトニコチン共役(chitosan- mercaptonicotinic acid conjugates) [Millotti et al. Biomacromolecules, 10 (2009) 3023-3027]、又はキトサン グルタチオン共役(chitosan- glutathione conjugates) [Kafedjiiski et al., Pharm Res., 22 (2005) 1480-1488]、又はペクチン−システイン結合体(pectin-cysteine conjugates)の様なチオール化されたペクチン(thiolated pectins) [Majzoob et al., J. Pharm. Pharmacol., 58 (2006) 1601-1610]、又はペクチン−4−メルカプトアミノフェノール共役(pectin-4-mercaptoaminophenol conjugate)[Perera et al., AAPS PharmSciTech. , 11 (2010) 174-180]、アルギン酸- システイン共役(alginate-cysteine conjugates)の様なチオール化されたアルギン酸(thiolated alginate) [Bernkop-Schnurch et al., J. Control. Release, 71 (2001) 277-285]、ヒアルロン酸‐システイン エチル エステル結合体(hyaluronic acid-cysteine ethyl ester conjugate)の様なチオール化されたヒアルロン酸(thiolated hyaluronic acid)[Kafedjiiski et al., Int. J. Pharm., 343, (2007) 48-58]、ポリアリルアミン-チオグリコール酸結合体(polyallylamine-thioglycolic acid conjugates)、チオール化されたポリリシン(thiolated polylysine)、チオール化されたポリオルニチン(thiolated polyornithine)、チオール化されたポリアリルアミン(thiolated polyallylamine)、チオール化されたポリアミノアミド(thiolated polyaminoamide)、の様なカルボキシメチルセルロ−ス−システイン共役体(carboxymethylcellulose-cysteine conjugates) の様なチオール化されたセルロ−ス誘導体(thiolated cellulose derivatives) [Bernkop-Schnurch, Int. J. Pharm., 194, (2000) 239-247]、チオール化された(架橋)ポリビニルピロリドン(thiolated (crosslinked)polyvinylpyrrolidones)であって、これらはビニルピロリドン(vinylpyrrolidone)の重合中にS-アセチル−システイン アクリルアミド(S-acetyl-cysteine-acrylamide)の様なS保護のチオール基を持つビニル化合物を追加することにより生成されるポリビニルピロリドン、及びチオール化されたポリビニルピロリドン(thiolated polyvinylpyrrolidones)同様に生成されるチオール化された(架橋)メタアクリル酸/エチルアクリレートコポリマー(thiolated (crosslinked) (meth)acrylic acid/ethylacrylate co-polymers)である。
エチルアクリル酸(ethylacrylate)及び、さらにビニルアルコール(vinylalcohol),ビニルイミダゾール(vinylimidazole),ビニルカプロラクトン(vinylcaprolactone)又は(メタ)アクリルアミド((meth)acrylamide)の様なビニル下部構造を持つモノマーもまたS保護のチオール基を持つビニル化合物と任意の比率で重合させることができる。チオール基を持つリガンドはさらに以下の化合物に好適である:メルカプト安息香酸(mercaptobenzoic acid)、N−アセチル−システイン(N-acetyl-cysteine)、ホモシステイン(homocysteine)、3−チオ−プロピオン酸(3-thio-proprionic acid)、4−チオ−ブタン酸(4-thio-butanoic acid)、チオブチルアミジン(thiobutylamidine)及びチオエチルアミジン(thioethylamidine) [Kafedjiiski et al., Biomaterials, 27 (2006) 127-135] である。
チオール下部構造のタンパク質構造は本発明のポリマーと反応することがあり得るからである。マニキュア液、メークアップ及び発汗抑制剤での使用もまた有益である。タンパク質中のシステイン下部構造のため皮もまた自由チオール基を持つため、本発明のポリマーはまた皮の含浸にも有用である。本発明のポリマーのラッカー及び種々の洗浄剤及び潤滑剤として適用することも可能である。
(1) 2-及び6-メルカプト(イソ)ニコチンアミドとのジスルフィドの形で利用が可能なチオール下部構造を持つポリマー化合物である。
リマーのチオール化は、システイン、システアミン、N‐アセチルシステイン、チオグリコール酸、メルカプト安息香酸、メルカプトニコチン酸、グルタチオン又はメルカプトアニリンとアミド結合を形成することにより実現される。
以下の実施例は本発明の代表的な例を開示する。以下の実施例の改変及び種々の変更は本発明の範囲内で実施することができる。
6−メルカプトニコチンアミドの合成
5.0 gの6-クロロ-ニコチンアミド (31.9 mmol) 及び2.65 gのチオ尿素 (34.8 mmol)が無水アルコール(50 ml)中で懸濁され、還流下で6時間加熱された(加熱槽温度:約90℃)。反応混合物は時間の経過と共に黄色に変色した。その後反応混合物は室温に冷却された。生成されたS-(5−カルバミルー2−ピリジル)チウロリニウムクロライド(S-(5-carbamyl-2- pyridyl)thiuroniumchloride)がろ過により分離され、乾燥された。6.7 g の目標の化合物 (90 %)が黄色粉末として分離された。1H-NMR (200 MHz, DMSO-d6、δ):7.76 (br s, 1H); 7.83 (d, 1 H, J = 8.4 Hz); 8.33 (dd, 1 H, J = 8.4 Hz, J =2.0 Hz); 8.38 (br s, 1 H); 9.05 (d, 1 H, J = 2.0 Hz); 9.69 (brs, 4 H)。6.7 g の S-(5−カルバミルー2−ピリジル)チウロニウムクロライド(S-(5-carbamyl-2-pyridyl)thiuronium chloride) (28.8 mmol)が水(30 ml) 中で懸濁され、そして20 mlの5 MのNaOHが加えられた。懸濁液が室温で30分間攪拌された。その後pHが氷酢酸の添加により4.9に調整された。生の製品がろ過により分離され、適切な溶媒中(例えば、水)で再結晶させ、目標の化合物(クロロニコチンアミドが69%)3.4gが黄色粉末の形で生成された。1H-NMR (200 MHz, DMSO-d6, δ) : 7.29 (d, 1 H, J = 9.1 Hz); 7.46 (br s, 1H); 7.76 (dd, 1 H, J = 9.1 Hz, J = 2.2 Hz); 7.95 (br s, 1 H) ; 8.13 (d, 1 H, J = 2.2 Hz); 13.74 (br s, 1 H).
実施例2:
ポリアクリル酸−システイン−6−メルカプトニコチンアミド共役の合成
450 kDa (Sigma-Aldrich, Vienna)ポリアクリル酸1gが200mlの脱塩水中で水和され、そしてpHが1MのNAOHの添加で5に調整された。ポリマーのカルボン酸グループに室温で、l-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) carbodiimide
hydrochloride)が添加され、30分攪拌することで事前に活性化され、最終濃度が200 mMとされた。
キトサン―チオグリコール酸―2−又は6−メルカプトニコチンアミド−共役
1グラムのキトサンが10 mlの1 M HCl中で水和され、続いて脱塩水で希釈され1% (m/v)の最終濃度とされた。1gのチオグリコール酸(TGA)及び最終濃度200 mMのl-エチル-3-(3-ジメチルアミノプロピル)カルボジイジミド塩酸塩((l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride)が添加され、必要な場合は1 M HC1又は1 M NaOHによりpHが5に調整される。そして反応混合物は室温で6時間攪拌された。共役は、1mMの水性塩酸溶液により透析され、同じ透析媒体であるが2度透析され、さらに1%のNaCIを含む透析媒体に対し透析され、そして最終的に遮光条件下で10℃の水により透析された。その後共役のpHは5に調整された。単離された共役は−30℃で凍結乾燥されそして4℃で保存された。共役結合したチオール基の量がEllman試薬により決定された。
ペクチン−4−アミノチオフェノ−ル−2−メルカプトニコチンアミド共役の合成
1グラムのペクチンが250 mlの水/ジオキサン(2+1)中に溶解された。3 mlのジオキサン中に溶解された0.2 gの4-メルカプトアニリンを連続して添加した後に、pHが0.5 M NaOHにより4.5に調整され、l-エチル-3-(3-ジメチルアミノプロピル)カルボジイジミド塩酸塩(l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride)が200mMの最終濃度で添加された。室温で3時間攪拌した後にpHが7.5に調整され、0.2gの水素化ホウ素ナトリウムが添加された。反応混合物は4℃で1時間攪拌された。その後未結合の4-メルカプトアニリンが酢酸エチルにより数度に渡り抽出して除去された。生成された共役はイソプロピルアルコールを添加して沈殿させ、そして沈殿物は純イソプロピルアルコール及びアセトンで洗浄された。精製された共役物は乾燥器で乾燥された。
粘膜付着性試験
実施例3に記載の方法で合成されたポリマーの粘膜付着特性がBernkop-Schnurch他の示す方法により決定された[Bernkop-Schnurch et al., Int. J. Pharm., 260 (2003) 229-237]。メルカプトニコチンアミド下部構造を持つ、又は持たないポリマーが直径5mmの錠剤(30mg)に圧縮調剤された。続いて鋼製シリンダに載せた、新たに切除された豚の小腸粘膜に低圧で付着された。シリンダは欧州薬局方に従い、37℃でpH6.5の50mMのリン酸緩衝液で満たした溶解試験装置中で100回転/分で攪拌された。粘膜から錠剤を分離する時点は視認により決定された。この結果は図2(平均+−標準偏差;n=4)に示す。
流動学的研究
0.25 gのキトサン−チオグリコール酸−6−メルカプトニコチンアミドが50mlの脱塩水中で水和された。生成されたゲルは50mlの0.5% (m/v)キトサン−チオグリコール酸溶液に添加された。反応混合物は均質化され、pHが6.0に調整された。図3に示す各点においてゲルの粘度が測定(1HZの一定周波数による振動測定)された。図3に示す様に粘度は数時間内に1000倍より大きく増大する(平均+−標準偏差;n=4)。
錠剤の調製
20gのポリアクリル酸−システインー6−メルカプトニコチンアミド(実施例2)が1gのミコナゾールにより均質化され、直接0.2g重量の錠剤に圧縮調製された。これらの錠剤は十分高い粘着特性を持ち、抗真菌性薬剤を制御される形で放出することを示す。
点鼻薬の調製
0.1 gのキトサン−チオグリコール酸−6−メルカプトニコチンアミド(実施例3)及び0.05 gのオキシメタゾリンHCLが100 mlの脱塩水で溶解され、10 mlのスポイド瓶に移された。任意選択的に最終濃度0.015% (m/v) の塩化ベンズアルコニウム及び最終濃度0.05% (m/v)のEDTAが保存料として添加された。
整髪用ジェルの調製
0.25 gのキトサン−チオグリコール酸−6−メルカプトニコチンアミド(実施例3)及び0.25 gのキトサン−チオグリコール酸(実施例3)が100mlの水/イソプロピルアルコール(9+1)中で水和された。もし必要なら1 M HC1又は1 M NaOHによりpHが6.0に調整される。生成されたジェルはアルミ/プラスチック複合体の小袋に各10mlを充填される。小袋を開封して髪に振りかけた後に、ジェルの粘度が大きく増大し、髪の型及び形を整える効果を発揮する。
Claims (12)
- 粘膜付着性ポリマー化合物の粘膜付着特性を高めるための2−(イソ)ニコチンアミド−ジスルフィド鎖、6−(イソ)ニコチンアミド−ジスルフィド鎖、6−ピリドキシン−ジスルフィド鎖又はニコチン酸ージスルフィド鎖を有するポリマー化合物の使用であって、前記粘膜付着性ポリマー化合物は
チオール化された下記の化合物、すなわち、
- (架橋)ポリ(メタ)アクリレート
- キトサン
- ペクチン
- アルギン酸
- ヒアルロン酸
- ポリアリルアミン-チオグリコール酸結合体
- ポリリシン、ポリオルニチン、ポリアミノアミド、セルロ−ス誘導体
- (架橋)ポリビニルピロリドン、これは重合中にS保護のチオール基を持つビニル化合物を追加することにより生成される、及び
- (架橋)メタアクリル酸/エチルアクリレートコポリマー、これは重合中にS保護のチオール基を持つビニル化合物を追加することにより生成される、
から選択され、
前記粘膜付着性ポリマー化合物が
2−(イソ)ニコチンアミド−ジスルフィド鎖、
6−(イソ)ニコチンアミド−ジスルフィド鎖、
6−ピリドキシン−ジスルフィド鎖、又は
ニコチン酸ージスルフィド鎖
と共有結合している、前記ポリマー化合物である、
前記使用。 - 以下に示すポリマー化合物であって、医薬品又は化粧品製品として使用される2−(イソ)ニコチンアミド−ジスルフィド側鎖、6−(イソ)ニコチンアミド−ジスルフィド側鎖、6−ピリドキシン−ジスルフィド側鎖又はニコチン酸ージスルフィド側鎖を含み、
前記ポリマー化合物は
チオール化された下記の化合物、すなわち、
- (架橋)ポリ(メタ)アクリレート
- キトサン
- ペクチン
- アルギン酸
- ヒアルロン酸
- ポリアリルアミン-チオグリコール酸結合体
- ポリリシン、ポリオルニチン、ポリアミノアミド、セルロ−ス誘導体
- (架橋)ポリビニルピロリドン、これは重合中にS保護のチオール基を持つビニル化合物を追加することにより生成される、及び
- (架橋)メタアクリル酸/エチルアクリレートコポリマー、これは重合中にS保護のチオール基を持つビニル化合物を追加することにより生成される、
から選択され、
前記の粘膜付着性ポリマー化合物が
2−(イソ)ニコチンアミド−ジスルフィド鎖、
6−(イソ)ニコチンアミド−ジスルフィド鎖、
6−ピリドキシン−ジスルフィド鎖、又は
ニコチン酸ージスルフィド鎖
と共有結合している、
前記ポリマー化合物。 - 請求項2のポリマー化合物の粘膜付着性製品としての使用。
- 請求項1又は3の使用であり、前記側鎖は、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−(ホモ)システイン−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−システアミン−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−N‐アセチルシステイン−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−チオグリコール酸−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−3−チオプロピオン酸−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−4−チオブタン酸−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−メルカプト安息香酸−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−メルカプトニコチン酸−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−グルタチオン−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−チオエチルアミジン−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−4−チオブチルアミジン−ジスルフィド、又は
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−メルカプトアニリン−ジスルフィド、から選択され、前記側鎖は、アミド、アミジン又はエステル結合により前記ポリマーに結合している、前記使用。 - 請求項3又は4の使用であり、粘膜付着活性ポリマー化合物はチオール化された下記の化合物、すなわち、
- (架橋)ポリ(メタ)アクリレート
- キトサン
- ペクチン
- アルギン酸
- ヒアルロン酸
- ポリアリルアミン-チオグリコール酸結合体
- ポリリシン、ポリオルニチン、ポリアミノアミド、セルロ−ス誘導体
- (架橋)ポリビニルピロリドン、これは重合中にS保護のチオール基を持つビニル化合物を追加することにより生成される、
- (架橋)メタアクリル酸/エチルアクリレートコポリマー、
から選択される、前記使用。 - 前記ポリマー化合物において、ポリマー1グラム当たり10-1000μmolのメルカプト(イソ)ニコチンアミド又はメルカプトピリドキシン部分構造が存在する、請求項1、3乃至5のいずれか1項の使用。
- 前記ポリマー化合物において、ポリマー1グラム当たり100-1000μmolのメルカプト(イソ)ニコチンアミド又はメルカプトピリドキシン部分構造が存在する、請求項5の使用。
- 粘膜付着性ポリマー化合物はチオール化された下記の化合物、すなわち、
- (架橋)ポリ(メタ)アクリレート
- キトサン
- ペクチン
- アルギン酸
- ヒアルロン酸
- ポリアリルアミン-チオグリコール酸結合体
- ポリリシン、ポリオルニチン、ポリアミノアミド、セルロ−ス誘導体
- (架橋)ポリビニルピロリドン、これは重合中にS保護のチオール基を持つビニル化合物を追加することにより生成される、及び
- (架橋)メタアクリル酸/エチルアクリレートコポリマー、これは重合中にS保護のチオール基を持つビニル化合物を追加することにより生成される、
から選択され、
前記ポリマー化合物が
2−(イソ)ニコチンアミド−ジスルフィド鎖、
6−(イソ)ニコチンアミド−ジスルフィド鎖、
6−ピリドキシン−ジスルフィド鎖、又は
ニコチン酸ージスルフィド鎖
と共有結合している、前記ポリマー化合物。 - 前記ポリマー化合物が
2−(イソ)ニコチンアミド−ジスルフィド鎖、
6−(イソ)ニコチンアミド−ジスルフィド鎖、又は
6−ピリドキシン−ジスルフィド鎖
と共有結合している、請求項8のポリマー化合物。 - 前記ポリマー化合物が
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−(ホモ)システイン−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−システアミン−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−N‐アセチルシステイン−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−チオグリコール酸−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−3−チオプロピオン酸−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−4−チオブタン酸−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−メルカプト安息香酸−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−メルカプトニコチン酸−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−グルタチオン−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−チオエチルアミジン−ジスルフィド、
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−4−チオブチルアミジン−ジスルフィド、又は
S‐(2‐又は6−メルカプト(イソ)ニコチンアミド)−又はS‐(6‐メルカプトピリドキシン)−メルカプトアニリン−ジスルフィドに、アミド、アミジン又はエステル結合により共有結合している、請求項9のポリマー化合物。 - 前記ポリマー化合物が(架橋)ポリ(メタ)アクリレート、キトサン、及びペクチンから選択される、請求項8乃至10のいずれか1項のポリマー化合物。
- 請求項8のポリマー化合物であって、医薬品又は化粧品用粘膜付着製品の調製のための2−(イソ)ニコチンアミド−ジスルフィド側鎖、6−(イソ)ニコチンアミド−ジスルフィド側鎖、6−ピリドキシン−ジスルフィド側鎖、又はニコチン酸ージスルフィド側鎖を含む、前記ポリマー化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT15402009 | 2009-09-30 | ||
ATA1540/2009 | 2009-09-30 | ||
PCT/EP2010/064464 WO2011039259A2 (de) | 2009-09-30 | 2010-09-29 | Mukoadhäsive polymere mit vitamin b-teilstrukturen |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013506728A JP2013506728A (ja) | 2013-02-28 |
JP6016234B2 true JP6016234B2 (ja) | 2016-10-26 |
Family
ID=43735171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012531410A Active JP6016234B2 (ja) | 2009-09-30 | 2010-09-29 | ビタミンb部分構造を持つ粘膜付着性ポリマー |
Country Status (11)
Country | Link |
---|---|
US (2) | US8980238B2 (ja) |
EP (1) | EP2482852B1 (ja) |
JP (1) | JP6016234B2 (ja) |
CN (2) | CN103709280B (ja) |
AU (1) | AU2010303009C1 (ja) |
CA (1) | CA2775833C (ja) |
DK (1) | DK2482852T3 (ja) |
ES (1) | ES2659442T3 (ja) |
IN (1) | IN2012DN03140A (ja) |
PL (1) | PL2482852T3 (ja) |
WO (1) | WO2011039259A2 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2659442T3 (es) | 2009-09-30 | 2018-03-15 | Thiomatrix Forschungs- Und Beratungs Gmbh | Polímeros mucoadhesivos con estructuras parciales de vitamina B |
EP3006045B3 (en) | 2014-10-07 | 2021-03-17 | Cyprumed GmbH | Pharmaceutical formulations for the oral delivery of peptide or protein drugs |
FR3039765B1 (fr) * | 2015-08-07 | 2018-08-24 | Oreal | Procede cosmetique de traitement des matieres keratiniques |
CA2997343A1 (en) | 2015-10-07 | 2017-04-13 | Cyprumed Gmbh | Pharmaceutical formulations for the oral delivery of peptide drugs |
WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
AR110125A1 (es) | 2016-11-07 | 2019-02-27 | Croma Pharma Ges M B H | Compuestos poliméricos que liberan sulfuro de hidrógeno |
JP7442823B2 (ja) | 2018-04-06 | 2024-03-05 | シプルメット・ゲーエムベーハー | 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物 |
CN108992703A (zh) * | 2018-08-17 | 2018-12-14 | 佛山市森昂生物科技有限公司 | 一种高透气性医用凝胶材料的制备方法 |
CN115315250A (zh) * | 2020-02-07 | 2022-11-08 | 生物粘附眼科公司 | 基于预活化的巯基化聚合物的黏膜黏附固体或半固体眼部传递系统 |
CN116419750A (zh) | 2020-09-07 | 2023-07-11 | 西普鲁梅有限公司 | 改进的glp-1受体激动剂的药物制剂 |
CA3227607A1 (en) | 2021-08-03 | 2023-02-09 | Jean CUINE | Mucoadhesive ocular delivery system for the treatment of glaucoma |
WO2023166179A1 (en) | 2022-03-03 | 2023-09-07 | Cyprumed Gmbh | Improved oral pharmaceutical formulations of therapeutic peptides and proteins |
WO2023248248A1 (en) * | 2022-06-21 | 2023-12-28 | L'oréal | Solubilization of thiopyridinone compound and composition comprising same |
CN116759581B (zh) * | 2023-08-17 | 2024-04-19 | 广东工业大学 | 一种用于锂离子电池硅基负极的硫醇化聚丙烯酸水性聚合物粘结剂及其制备方法和应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4169923A (en) * | 1974-10-15 | 1979-10-02 | Paolo Ferruti | High polymers containing nicotinic acid, process for their preparation and their use |
CS200754B1 (en) | 1978-06-19 | 1980-09-15 | Dusan Podhradsky | Polythioglycoloyloxyethylmethacrylate and process for preparing thereof |
US4521425A (en) * | 1981-11-02 | 1985-06-04 | Grassetti Davide R | Agents affecting the production of hormones in living mammals |
ZA858074B (en) * | 1984-11-06 | 1986-06-25 | Exovir Inc | Antiwrinkle cosmetic preparation |
CA1239357A (en) * | 1984-12-07 | 1988-07-19 | That T. Ngo | Method of activating polymeric carrier |
JPS63213854A (ja) * | 1987-03-03 | 1988-09-06 | Canon Inc | 電子写真感光体 |
DE3726454A1 (de) * | 1987-08-08 | 1989-02-16 | Behringwerke Ag | Thiolgruppenhaltige polymere, verfahren zu ihrer herstellung und ihre verwendung |
JPH01259001A (ja) * | 1988-04-08 | 1989-10-16 | Kuraray Co Ltd | 活性ジスルフイド基含有共重合体 |
FR2699184B1 (fr) * | 1992-12-16 | 1995-03-10 | Flamel Tech Sa | Nouveaux dérivés de collagène, leur procédé d'obtention et leur application à la préparation de biomatériaux. |
AU7870694A (en) | 1994-09-06 | 1996-03-27 | Ekagen Corporation | Polymeric resin for disulfide bond synthesis |
AT406054B (de) * | 1998-11-04 | 2000-02-25 | Andreas Bernkop-Schnuerch | Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung |
WO2001032623A1 (en) * | 1999-10-29 | 2001-05-10 | University Of Utah Research Foundation | An activated-thiol polymer for drug delivery |
EP1793873B1 (en) * | 2004-08-03 | 2013-08-07 | Tissuemed Limited | Tissue-adhesive materials |
CZ300805B6 (cs) | 2007-01-23 | 2009-08-12 | Ústav experimentální medicíny AV CR | Biomateriál na bázi nanovlákenných vrstev a zpusob jeho prípravy |
EP2167044A1 (en) * | 2007-06-11 | 2010-03-31 | BioCure, Inc. | Mucoadhesive vesicles for drug delivery |
ES2659442T3 (es) | 2009-09-30 | 2018-03-15 | Thiomatrix Forschungs- Und Beratungs Gmbh | Polímeros mucoadhesivos con estructuras parciales de vitamina B |
-
2010
- 2010-09-29 ES ES10760673.3T patent/ES2659442T3/es active Active
- 2010-09-29 AU AU2010303009A patent/AU2010303009C1/en active Active
- 2010-09-29 EP EP10760673.3A patent/EP2482852B1/de active Active
- 2010-09-29 JP JP2012531410A patent/JP6016234B2/ja active Active
- 2010-09-29 CN CN201310573913.8A patent/CN103709280B/zh active Active
- 2010-09-29 PL PL10760673T patent/PL2482852T3/pl unknown
- 2010-09-29 IN IN3140DEN2012 patent/IN2012DN03140A/en unknown
- 2010-09-29 US US13/499,099 patent/US8980238B2/en active Active
- 2010-09-29 WO PCT/EP2010/064464 patent/WO2011039259A2/de active Application Filing
- 2010-09-29 DK DK10760673.3T patent/DK2482852T3/en active
- 2010-09-29 CA CA2775833A patent/CA2775833C/en active Active
- 2010-09-29 CN CN2010800405370A patent/CN102596253B/zh active Active
-
2015
- 2015-02-12 US US14/621,313 patent/US10639377B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2775833C (en) | 2018-01-16 |
CN102596253B (zh) | 2013-11-06 |
US20120225024A1 (en) | 2012-09-06 |
DK2482852T3 (en) | 2018-03-05 |
IN2012DN03140A (ja) | 2015-09-18 |
EP2482852A2 (de) | 2012-08-08 |
CN102596253A (zh) | 2012-07-18 |
CA2775833A1 (en) | 2011-04-07 |
CN103709280A (zh) | 2014-04-09 |
AU2010303009A1 (en) | 2012-03-01 |
WO2011039259A2 (de) | 2011-04-07 |
WO2011039259A3 (de) | 2011-10-20 |
ES2659442T3 (es) | 2018-03-15 |
PL2482852T3 (pl) | 2018-05-30 |
AU2010303009C1 (en) | 2016-01-07 |
US8980238B2 (en) | 2015-03-17 |
US10639377B2 (en) | 2020-05-05 |
JP2013506728A (ja) | 2013-02-28 |
EP2482852B1 (de) | 2017-11-22 |
AU2010303009B2 (en) | 2015-07-16 |
US20150209434A1 (en) | 2015-07-30 |
CN103709280B (zh) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6016234B2 (ja) | ビタミンb部分構造を持つ粘膜付着性ポリマー | |
Chatterjee et al. | Mucoadhesive polymers and their mode of action: A recent update | |
Leichner et al. | Thiolated polymers: Bioinspired polymers utilizing one of the most important bridging structures in nature | |
Bonengel et al. | Thiomers—From bench to market | |
Chaturvedi et al. | Polymeric hydrogels for oral insulin delivery | |
Kafedjiiski et al. | Synthesis and in vitro evaluation of a novel thiolated chitosan | |
Perrone et al. | Preactivated thiolated glycogen as mucoadhesive polymer for drug delivery | |
Perrone et al. | S-preactivated thiolated glycol chitosan useful to combine mucoadhesion and drug delivery | |
Ho et al. | Thiol-modified chitosan sulfate nanoparticles for protection and release of basic fibroblast growth factor | |
Hanif et al. | Thiomers: a blessing to evaluating era of pharmaceuticals | |
Mali et al. | Delivery of drugs using tamarind gum and modified tamarind gum: A review | |
JP2002528518A (ja) | 粘液付着性ポリマー、その使用およびその製造法 | |
Puri et al. | Overview of mucoadhesive biopolymers for buccal drug delivery systems | |
Singh et al. | Enhancement of mucoadhesive property of polymers for drug delivery applications | |
WO2013082196A1 (en) | bFGF-POLYMER CONJUGATES, METHODS FOR MAKING THE SAME AND APPLICATIONS THEREOF | |
Ugoeze | Bioadhesive polymers for drug delivery applications | |
Nazar et al. | Hydrogels in mucosal delivery | |
Cheng et al. | Grafted polysaccharides as advanced pharmaceutical excipients | |
Du et al. | Controlled release of a model protein drug ovalbumin from thiolated hyaluronic acid matrix | |
Mogoşanu et al. | Pharmaceutical natural polymers: structure and chemistry | |
Jain et al. | Thiolated Chitosan as an improved bioadhesive polymer in drug delivery | |
Singh et al. | Mucoadhesive Drug Delivery System and There Future Prospective: Are a Promising Approach for Effective Treatment? | |
BR112012020223B1 (pt) | Pélete farmacêutico de fator de crescimento epidérmico administrável por via oral, uso e processo de preparação do mesmo, bem como cápsula compreendendo o referido pélete | |
Wagh et al. | Thiomers: a new generation of mucoadhesive polymers | |
Junginger | Polymeric permeation enhancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130705 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140311 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140605 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140612 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140704 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140714 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140808 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140828 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140910 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150324 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150623 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150723 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150821 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150916 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160301 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160801 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160823 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160921 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6016234 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |